Sentences with phrase «advanced lung tumor»

The researchers now have plans to conduct further work to explore the safety and effectiveness of the approach in vivo and in advanced lung tumor mouse models.

Not exact matches

«What is particularly encouraging is that we are now able to select, based on features in the tumor, approximately a quarter of advanced lung cancer patients who can receive immunotherapy as their initial treatment.

An old idea of retreating lung tumors with radiation is new again, especially with the technological advances seen in radiation oncology over the last decade.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

«FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness: Insights derived from FDG PET could improve treatment selection for patients with advanced non-small cell lung cancer.»

Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC).

Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient - matched tumor tissue DNA.

In a study of 124 patients with advanced breast, lung, and prostate cancers, a new, high - intensity genomic sequencing approach detected circulating tumor DNA at a high rate.

«Metastatic brain tumors — often from lung, breast or skin cancers — are the most commonly observed tumors within the brain and account for about 40 percent of advanced melanoma metastases.

«Metastatic brain tumors — often from lung, breast or skin cancers — are the most commonly observed tumors within the brain and account for about 30 percent of advanced breast cancer metastases,» says Khalid Shah, MS, PhD, director of the Molecular Neurotherapy and Imaging Laboratory in the MGH Departments of Radiology and Neurology, who led the study.

An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial showing that, among 236 patients with various types of cancer, the treatment shrank tumors in 28 percent of melanoma patients, 30 percent of patients with kidney cancer, and 18 percent of patients with advanced non-small cell lung cancer.

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could aLung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.

In the study, the researchers tested phenformin as a chemotherapy agent in genetically - engineered mice lacking LKB1 and which had advanced stage lung tumors.

In 2010, CRI researchers Drew Pardoll, M.D., Ph.D., Susan Topalian, M.D., and colleagues completed a phase I study showing that a PD -1-specific monoclonal antibody induces frequent tumor regressions in patients with advanced melanoma, renal cancer, lung cancer, and colon cancer with very low rates of toxicity.

To translate advances in our understanding of molecular mechanisms of oncogenesis and tumor progression into novel therapeutic strategies.With primary focus on lung cancer, melanoma, and lymphoma / leukemia, we will use the strength of in - depth molecular and phenotypic characterization of tumor heterogeneity to identify new targets and translate those into new therapeutic opportunities.

Not all cases are so advanced that tumors in the lungs can be detected.

Cats with advanced lung involvement at the time the tumor is diagnosed have a median survival time of only one month.

A few dogs are diagnosed with advanced metastasis (tumors that have spread to elsewhere in the body, such as the lungs and lymph nodes) and might be feeling ill from their tumors when they come for treatment.